Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901419 | 0.90 | SIGMAR1 (0.55) | SIGMAR1CDK1KDRPOLBL3MBTL3 | |
| SCHEMBL13283790 | 0.80 | SIGMAR1 (0.53) | SIGMAR1CDK1KDRPOLBL3MBTL3 | |
| SCHEMBL14980018 | 0.79 | SIGMAR1 (0.55) | SIGMAR1CDK1KDRPOLBL3MBTL3 | |
| SCHEMBL13996572 | 0.78 | POLB (0.50) | POLBMAPTMEN1KMT2ALMNA | |
| SCHEMBL15137345 | 0.77 | SIGMAR1 (0.57) | SIGMAR1CDK1KDRPOLBL3MBTL3 | |
| SCHEMBL24022514 | 0.77 | SIGMAR1 (0.60) | SIGMAR1POLBL3MBTL3KMT2ATHRA | |
| SCHEMBL23805529 | 0.76 | SIGMAR1 (0.82) | SIGMAR1CDK1KDRPOLBL3MBTL3 | |
| SCHEMBL8009145 | 0.76 | SIGMAR1 (0.55) | SIGMAR1POLBL3MBTL3EPHX2MAPT | |
| SCHEMBL15034748 | 0.76 | HRH3 (0.59) | SIGMAR1L3MBTL3HRH3 | |
| SCHEMBL3637477 | 0.75 | SIGMAR1 (0.51) | SIGMAR1POLBL3MBTL3EPHX2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | SIGMAR1 2384/4885CDK1 195/4885KDR 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.